SAN DIEGO, Jan. 12, 2011 /PRNewswire/ -- Genelux Corporation, a privately held, San Diego-based biopharmaceutical company developing novel therapies against cancer, today announced that its Board of Directors has appointed Jodi Devlin as the company's President effective January 10, 2011. Dr. Aladar Szalay, the company's Founder, will continue to serve as CEO and Chairman of the Board.
"Ms. Devlin is an excellent choice to lead Genelux Corporation into the next phase of growth, from commercializing the Company's leading cancer therapy to transforming the Company's operations accordingly," said Dr. Aladar Szalay, Founder, Chairman and CEO. "She brings two decades of extensive commercialization and executive management experience at one of the world's leading pharmaceutical companies to Genelux and has the vision and energy to help us realize our goals."
Ms. Devlin's experience spans a broad range of functions including commercialization, clinical development, strategic business development and planning. Most recently, Ms. Devlin served as Vice President at Abbott where she led Global Pipeline Marketing for all therapeutic areas, including oncology. Over the course of her career, Ms. Devlin held positions as Vice President of International Marketing, U.S. Specialty Operations, Primary Care and Virology. Under her leadership, HUMIRA®, Kaletra® and TriCor® all achieved multi-billion dollar status. Ms. Devlin holds a BS in Nursing from the University of Oklahoma and an MBA from Washington University Olin School of Business.
"We are very pleased that Ms. Devlin will be joining our team at an exciting time in the company's evolution," said Dr. Szalay. "Her proven leadership and management capabilities have prepared her well for this new challenge. She is a competent professional and knows how to bring a product successfully to market. We believe she has the right combination of experie
|SOURCE Genelux Corporation|
Copyright©2010 PR Newswire.
All rights reserved